Hematopoietic Cell Transplantation for Central Nervous System Embryonal Tumors and Ependymoma

Policy # 00063
Original Effective Date: 01/28/2002
Current Effective Date: 07/10/2023

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Autologous Hematopoietic Cell Transplantation for Malignant Astrocytomas and Gliomas is addressed separately in medical policy 00058.

Note: Hematopoietic Cell Transplantation for Solid Tumors of Childhood is addressed separately in medical policy 00064.

When Services Are Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

Autologous Hematopoietic Cell Transplantation
Based on review of available data, the Company may consider autologous hematopoietic cell transplantation (HCT) as consolidation therapy for previously untreated embryonal tumors of the central nervous system (CNS) that show partial or complete response (PR or CR) to induction chemotherapy, or stable disease after induction therapy to be eligible for coverage** (See Note below).

Based on review of available data, the Company may consider autologous hematopoietic cell transplantation (HCT) to treat recurrent embryonal tumors of the central nervous system (CNS) to be eligible for coverage.**

Note: In general, use of autologous HCT for previously untreated medulloblastoma has shown no survival benefit for those individuals considered to be at average risk (i.e., patient age older than three years, without metastatic disease, and with total or near total surgical resection [< 1.5 cm² residual tumor]) when compared to conventional therapies.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Autologous Hematopoietic Cell Transplantation
Based on review of available data, the Company considers tandem autologous hematopoietic cell transplantation (HCT) to treat embryonal tumors of the central nervous system (CNS) to be investigational.*

Allogeneic Hematopoietic Cell Transplantation
Based on review of available data, the Company considers allogeneic hematopoietic cell transplantation (HCT) to treat embryonal tumors of the central nervous system (CNS) to be investigational.*

Ependymoma
Based on review of available data, the Company considers autologous, tandem autologous and allogeneic hematopoietic cell transplantation (HCT) to treat ependymoma to be investigational.*

Background/Overview

Central Nervous System Embryonal Tumors
Classification of brain tumors is based on both histopathologic characteristics of the tumor and location in the brain. Central nervous system (CNS) embryonal tumors are more common in children and are the most common brain tumor in childhood. Medulloblastomas account for 20% of all childhood CNS tumors.

Recurrent childhood CNS embryonal tumors is not uncommon and, depending on which type of treatment the patient initially received, autologous hematopoietic cell transplantation (HCT) may be an option. For patients who receive high-dose chemotherapy and autologous HCT for recurrent embryonal tumors, the objective response is 50% to 75%; however, long-term disease control is obtained in fewer than 30% of patients and is primarily seen in patients with a first relapse of localized disease at the time of the relapse.
Ependymoma
Ependymoma is a neuroepithelial tumor that arises from the ependymal lining cell of the ventricles and is, therefore, usually contiguous with the ventricular system. An ependymoma tumor typically arises intracranially in children, while in adults a spinal cord location is more common. Ependymomas have access to the cerebrospinal fluid and may spread throughout the entire neuroaxis. Ependymomas are distinct from ependymoblastomas due to their more mature histologic differentiation.

Hematopoietic Cell Transplantation
Hematopoietic cell transplantation is a procedure in which hematopoietic stem cells are intravenously infused to restore bone marrow and immune function in cancer patients who receive bone marrow-toxic doses of cytotoxic drugs with or without whole-body radiotherapy. Hematopoietic stem cells may be obtained from the transplant recipient (autologous HCT) or a donor (allogeneic HCT [allo-HCT]). These cells can be harvested from bone marrow, peripheral blood, or umbilical cord blood shortly after delivery of neonates.

Immunologic compatibility between infused hematopoietic stem cells and the recipient is not an issue in autologous HCT. In allogeneic stem cell transplantation, immunologic compatibility between donor and patient is a critical factor for achieving a successful outcome. Compatibility is established by typing of human leukocyte antigens (HLA) using cellular, serologic, or molecular techniques. HLA refers to the gene complex expressed at the HLA-A, -B, and -DR (antigen-D related) loci on each arm of chromosome 6. An acceptable donor will match the patient at all or most of the HLA loci.

Conditioning for Hematopoietic Cell Transplantation

Conventional Conditioning
The conventional ("classical") practice of allo-HCT involves administration of cytotoxic agents (e.g., cyclophosphamide, busulfan) with or without total body irradiation at doses sufficient to cause bone marrow ablation in the recipient. The beneficial treatment effect of this procedure is due to a combination of the initial eradication of malignant cells and subsequent graft-versus-malignancy effect mediated by non-self-immunologic effector cells. While the slower graft-versus-malignancy effect is considered the potentially curative component, it may be overwhelmed by existing disease...
Hematopoietic Cell Transplantation for Central Nervous System Embryonal Tumors and Ependymoma

Policy # 00063
Original Effective Date: 01/28/2002
Current Effective Date: 07/10/2023

in the absence of pretransplant conditioning. Intense conditioning regimens are limited to patients who are sufficiently medically fit to tolerate substantial adverse effects. These include opportunistic infections secondary to loss of endogenous bone marrow function and organ damage or failure caused by cytotoxic drugs. Subsequent to graft infusion in allo-HCT, immunosuppressant drugs are required to minimize graft rejection and graft-versus-host disease (GVHD), which increases susceptibility to opportunistic infections.

The success of autologous HCT is predicated on the potential of cytotoxic chemotherapy, with or without radiotherapy, to eradicate cancerous cells from the blood and bone marrow. This permits subsequent engraftment and repopulation of the bone marrow with presumably normal hematopoietic stem cells obtained from the patient before undergoing bone marrow ablation. Therefore, autologous HCT is typically performed as consolidation therapy when the patient’s disease is in complete remission. Patients who undergo autologous HCT are also susceptible to chemotherapy-related toxicities and opportunistic infections before engraftment, but not GVHD.

Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation
Reduced-intensity conditioning (RIC) refers to the pretransplant use of lower doses of cytotoxic drugs or less intense regimens of radiotherapy than are used in traditional full-dose myeloablative conditioning treatments. Although the definition of reduced-intensity conditioning is variable, with numerous versions employed, all regimens seek to balance the competing effects of relapse due to residual disease and non-relapse mortality. The goal of RIC is to reduce disease burden and to minimize associated treatment-related morbidity and non-relapse mortality in the period during which the beneficial graft-versus-malignancy effect of allogeneic transplantation develops. Reduced-intensity conditioning regimens range from nearly total myeloablative to minimally myeloablative with lymphoa blation, with intensity tailored to specific diseases and patient condition. Patients who undergo RIC with allo-HCT initially demonstrate donor cell engraftment and bone marrow mixed chimerism. Most will subsequently convert to full-donor chimerism. In this review, the term reduced-intensity conditioning will refer to all conditioning regimens intended to be nonmyeloablative.

Autologous HCT allows for the escalation of chemotherapy doses above those limited by myeloablation and has been tried in patients with high-risk brain tumors in an attempt to eradicate residual tumor cells and improve cure rates. The use of allo-HCT for solid tumors does not rely on
Hematopoietic Cell Transplantation for Central Nervous System Embryonal Tumors and Ependymoma

Policy # 00063
Original Effective Date: 01/28/2002
Current Effective Date: 07/10/2023

the escalation of chemotherapy intensity and tumor reduction but rather on a graft-versus-tumor effect. Allo-HCT is not commonly used in solid tumors and may be used if an autologous source cannot be cleared of a tumor or cannot be harvested.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)
The U.S. Food and Drug Administration regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation, Title 21, parts 1270 and 1271. Hematopoietic stem cells are included in these regulations.

Rationale/Source
This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

High-dose chemotherapy with hematopoietic cell transplantation (HCT) has been investigated as a possible therapy in pediatric patients with brain tumors, particularly in those with high-risk disease. The use of HCT has allowed for a reduction in the dose of radiation needed to treat both average- and high-risk disease with a goal of preserving the quality of life and intellectual functioning.

Summary of Evidence
For individuals who have newly diagnosed central nervous system (CNS) embryonal tumors who receive autologous hematopoietic cell transplantation (HCT), the evidence includes prospective and retrospective studies. Relevant outcomes are overall survival (OS), disease-specific survival (DSS), and treatment-related mortality and morbidity. For pediatric CNS embryonal tumors, an important consideration is whether the use of HCT may allow for a reduction in radiation dose. Data from single-arm studies using high-dose chemotherapy with autologous HCT to treat newly diagnosed CNS embryonal tumors have shown comparable or improved survival (both EFS and OS) compared with historical controls treated with conventional therapy, with or without radiotherapy, particularly
Hematopoietic Cell Transplantation for Central Nervous System Embryonal Tumors and Ependymoma

Policy # 00063
Original Effective Date: 01/28/2002
Current Effective Date: 07/10/2023

in patients with a disease considered high-risk. In a retrospective comparative study, survival in patients receiving high-dose chemotherapy with HCT and delayed craniospinal irradiation (CSI) was comparable with survival in those receiving upfront CSI. Overall, data from these observational studies have suggested HCT may allow reduced doses of CSI without worsening survival outcomes. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have recurrent or relapsed CNS embryonal tumors who receive autologous HCT, the evidence includes prospective and retrospective single-arm studies and a systematic review of these studies. Relevant outcomes are OS, DSS, and treatment-related mortality and morbidity. For recurrent/relapsed CNS embryonal tumors, survival outcomes after HCT vary, and survival is generally very poor for tumors other than medulloblastoma. Data from some single-arm studies using autologous HCT to treat recurrent CNS embryonal tumors have shown comparable or improved survival compared with historical controls treated with conventional therapy for certain patients. The results of a 2012 systematic review of observational studies in patients with relapsed supratentorial PNET suggested that a subgroup of infants with the chemosensitive disease might benefit from autologous HCT, achieving survival without the use of radiotherapy, whereas outcomes in older children and/or in the pineal location are poor with this modality. However, a relatively large prospective multicenter study has reported that HCT was not associated with improved survival outcomes in patients who had a good response to therapy. Overall, data from these single-arm studies have suggested HCT may be associated with improved survival outcomes in select patients, although data for some tumor types are limited (eg, atypical teratoid/rhabdoid tumors). The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have CNS embryonal tumors who receive tandem autologous HCT, the evidence includes prospective and retrospective single-arm studies. Relevant outcomes are OS, DSS, and treatment-related mortality and morbidity. Less evidence specifically addresses the use of tandem autologous HCT for CNS embryonal tumors. The available single-arm studies are very small but appear to report OS and EFS rates comparable with single autologous HCT. Tandem transplants might allow reduced doses of craniospinal irradiation, with the goal of avoiding long-term radiation damage. However, most studies used standard-dose irradiation, making the relative benefit of tandem autologous HCT uncertain. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.
Hematopoietic Cell Transplantation for Central Nervous System Embryonal Tumors and Ependymoma

Policy # 00063
Original Effective Date: 01/28/2002
Current Effective Date: 07/10/2023

For individuals who have CNS embryonal tumors who receive allogeneic HCT, the evidence includes case reports. Relevant outcomes are OS, DSS, and treatment-related mortality and morbidity. The available evidence is limited. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have ependymoma who receive autologous HCT, the evidence includes relatively small case series. Relevant outcomes are OS, DSS, and treatment-related mortality and morbidity. The available case series do not report higher survival rates for patients with ependymoma treated with HCT compared with standard therapies. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Supplemental Information
Practice Guidelines and Position Statements
Guidelines or position statements will be considered for inclusion in ‘Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

National Comprehensive Cancer Network
Current National Comprehensive Cancer Network (NCCN; v.2.2022) guidelines on treating central nervous system tumors make the following recommendations about hematopoietic cell transplant (HCT):
- For medulloblastoma and supratentorial primitive neuroectodermal tumor, high-dose chemotherapy with autologous HCT for localized recurrent disease with maximum safe resection is a category 2A recommendation (based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate).

American Society for Blood and Marrow Transplantation
In 2015, the American Society for Blood and Marrow Transplantation (now referred to as the American Society for Transplantation and Cellular Therapy) published consensus guidelines on the use of HCT to treat specific conditions, in both clinical trial and clinical practice settings. These
guidelines were updated in 2020. Neither the 2015 nor the 2020 guidelines address HCT in treatment of ependymomas. The tumors addressed in this review for which the Society has provided recommendations are listed in Table 1.

**Table 1. Recommendations for Use of Autologous and Allogeneic Hematopoietic Cell Transplantation in Pediatric patients (<18 years)**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Treatment Option</th>
<th>2015 Recommendation</th>
<th>2020 Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuroblastoma, high-risk or relapse</td>
<td>Allogeneic HCT</td>
<td>Developmental</td>
<td>Developmental; tandem autologous HCT recommended over single transplant</td>
</tr>
<tr>
<td></td>
<td>Autologous HCT</td>
<td>Standard of care</td>
<td>Standard of care, clinical evidence available</td>
</tr>
<tr>
<td>Medulloblastoma, high-risk</td>
<td>Allogeneic HCT</td>
<td>Not generally recommended</td>
<td>Not generally recommended</td>
</tr>
<tr>
<td></td>
<td>Autologous HCT</td>
<td>Standard of care, clinical evidence available</td>
<td>Standard of care, clinical evidence available</td>
</tr>
<tr>
<td>Other malignant brain tumors</td>
<td>Allogeneic HCT</td>
<td>Not generally recommended</td>
<td>Not generally recommended</td>
</tr>
<tr>
<td></td>
<td>Autologous HCT</td>
<td>Standard of care, clinical evidence available</td>
<td>Standard of care, clinical evidence available</td>
</tr>
</tbody>
</table>

HCT: hematopoietic cell transplantation

**U.S. Preventive Services Task Force Recommendations**
Not applicable.

**Medicare National Coverage**
Hematopoietic Cell Transplantation for Central Nervous System Embryonal Tumors and Ependymoma

Policy # 00063
Original Effective Date: 01/28/2002
Current Effective Date: 07/10/2023

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials
Some currently ongoing or unpublished trials that might influence this review are listed in Table 2.

Table 2. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT00336024</td>
<td>A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High-Risk Medulloblastoma in Children &lt; 36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate</td>
<td>91</td>
<td>Dec 2016 (active, not recruiting )</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.

References

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Hematopoietic Cell Transplantation for Central Nervous System Embryonal Tumors and Ependymoma

Policy # 00063
Original Effective Date: 01/28/2002
Current Effective Date: 07/10/2023


Hematopoietic Cell Transplantation for Central Nervous System Embryonal Tumors and Ependymoma

Policy # 00063
Original Effective Date: 01/28/2002
Current Effective Date: 07/10/2023

Hematopoietic Cell Transplantation for Central Nervous System Embryonal Tumors and Ependymoma

Policy #  00063
Original Effective Date: 01/28/2002
Current Effective Date: 07/10/2023


©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Hematopoietic Cell Transplantation for Central Nervous System Embryonal Tumors and Ependymoma

Policy # 00063
Original Effective Date: 01/28/2002
Current Effective Date: 07/10/2023

Hematopoietic Cell Transplantation for Central Nervous System Embryonal Tumors and Ependymoma

Policy # 00063
Original Effective Date: 01/28/2002
Current Effective Date: 07/10/2023

Policy History
Original Effective Date: 01/28/2002
Current Effective Date: 07/10/2023
12/06/2001 Medical Policy Committee review
01/28/2002 Managed Care Advisory Council approval
05/07/2004 Medical Director review
05/18/2004 Medical Policy Committee review. Format revision. High-Dose Chemotherapy with Hematopoietic Stem-cell Support for Primitive Neuroectodermal policy developed separately from current HDC with Hematopoietic Stem-cell Support policy. No substance change to policy.
06/28/2004 Managed Care Advisory Council approval
05/03/2005 Medical Director review
05/17/2005 Medical Policy Committee review. Patient Selection criteria added to policy.
05/23/2005 Managed Care Advisory Council approval
08/03/2005 Medical Director review
08/16/2005 Medical Policy Committee review. Coverage eligibility changes: autologous BMT to consolidate a remission after initial therapy in high-risk patients with PNETs, excluding medulloblastoma and ependymoma is considered to be eligible for coverage.
08/24/2005 Managed Care Advisory Council approval
07/12/2006 Medical Director review
07/19/2006 Medical Policy Committee review. Format changes. FDA information added. Additional rationale/source was added.
07/10/2007 Medical Director review
07/18/2007 Medical Policy Committee approval. Statement added to deny investigational when patient selection criteria is not met.
11/07/2007 Medical Director review
11/05/2008 Medical Director review
11/18/2008 Medical Policy Committee approval. Coverage eligibility unchanged
11/12/2009 Medical Policy Committee approval

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Hematopoietic Cell Transplantation for Central Nervous System Embryonal Tumors and Ependymoma

Policy #  00063
Original Effective Date: 01/28/2002
Current Effective Date: 07/10/2023

11/04/2010  Medical Policy Committee review
11/16/2010  Medical Policy Implementation Committee approval. Policy title changed to remove “high-dose chemotherapy” and to change PNET to embryonal tumors. Policy statements reworded and separated to address ependymoma and embryonal CNS tumors specifically; however the intent of the policy remains the same.
11/03/2011  Medical Policy Committee approval
11/01/2012  Medical Policy Committee review
03/04/2013  Coding update
01/09/2014  Medical Policy Committee review
01/15/2014  Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
01/08/2015  Medical Policy Committee review
01/21/2015  Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/03/2015  Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.
04/07/2016  Medical Policy Committee review
04/20/2016  Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
01/01/2017  Coding update: Removing ICD-9 Diagnosis Codes
04/07/2017  Medical Policy Committee review
04/19/2017  Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
06/07/2018  Medical Policy Committee review
06/20/2018  Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
06/06/2019  Medical Policy Committee review
Hematopoietic Cell Transplantation for Central Nervous System Embryonal Tumors and Ependymoma

Policy # 00063
Original Effective Date: 01/28/2002
Current Effective Date: 07/10/2023

06/19/2019 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
06/04/2020 Medical Policy Committee review
06/10/2020 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
06/03/2021 Medical Policy Committee review
06/09/2021 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
06/02/2022 Medical Policy Committee review
06/08/2022 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
06/01/2023 Medical Policy Committee review
06/14/2023 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

Next Scheduled Review Date: 06/2024

Coding
The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2022 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Hematopoietic Cell Transplantation for Central Nervous System Embryonal Tumors and Ependymoma

Policy #  00063
Original Effective Date: 01/28/2002
Current Effective Date: 07/10/2023

Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>38204, 38205, 38206, 38207, 38208, 38209, 38210, 38211, 38212, 38213, 38214, 38215, 38230, 38240, 38241, 38242, 38243</td>
</tr>
<tr>
<td></td>
<td>Add code effective 06/01/2023: 38232</td>
</tr>
<tr>
<td>HCPCS</td>
<td>S2140, S2142, S2150</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>All related Diagnoses</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with technology evaluation center(s);
2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Hematopoietic Cell Transplantation for Central Nervous System Embryonal Tumors and Ependymoma

Policy #  00063
Original Effective Date: 01/28/2002
Current Effective Date: 07/10/2023

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

A. In accordance with nationally accepted standards of medical practice;
B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.